BridgeBio lands $100 million for Japan license to drug aimed at common cause of dwarfism

The Palo Alto company, with another drug facing a commercial battle with Pfizer in heart failure, in December dosed the first patient in a late-stage achondroplasia study.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks